This trial is testing a new cancer treatment that includes a combination of atezolizumab and platinum-based chemotherapy. The trial will compare the new treatment to placebo and best supportive care to see if it is more effective.
1 Primary · 19 Secondary · Reporting Duration: Up to approximately 96 months
453 Total Participants · 2 Treatment Groups
Primary Treatment: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody · Has Placebo Group · Phase 3
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: